identifying optimal patient subgroups in ovarian cancer for neoadjuvant parp inhibitor therapy
Published 1 month ago • 39 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
0:45
evaluating future use of parp inhibitors in neoadjuvant therapy for ovarian cancer
-
1:38
updates in parp inhibition for ovarian cancer
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
3:45
parp inhibitors for ovarian cancer
-
1:53
parp inhibitors: game-changers for ovarian cancer patients?
-
1:24
innovations in ovarian cancer treatment: parp inhibitors
-
39:03
the therapeutic potential of novel parp inhibitors in the clinic for epithelial ovarian cancer
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
1:08
should 1l maintenance with parp inhibitors be given to all patients with ovarian cancer?
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
1:30
dr. fowler on considerations for cytoreductive surgery in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising
-
3:31
distinguishing between parp inhibitors in breast cancer